137 related articles for article (PubMed ID: 11295103)
1. Relation of prenephrectomy CD profiles and serum cytokines to the disease outcome and response to IFN-alpha/IL-2 therapy in renal cell carcinoma patients.
Lauerová L; Dusek L; Spurny V; Simicková M; Rovny A; Rejthar A; Kocák I; Kovarík J
Oncol Rep; 2001; 8(3):685-92. PubMed ID: 11295103
[TBL] [Abstract][Full Text] [Related]
2. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.
Lauerová L; Dusek L; Simícková M; Rovný F; Spurný V; Rovný A; Slampa P; Zaloudík J; Rejthar A; Wotke J; Kovarík J
Neoplasma; 1999; 46(3):141-9. PubMed ID: 10613588
[TBL] [Abstract][Full Text] [Related]
3. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver.
Zaloudik J; Lauerova L; Janakova L; Talac R; Simickova M; Nekulova M; Mikulikova I; Kovarik J; Sheard M
Hepatogastroenterology; 1999; 46(25):220-7. PubMed ID: 10228796
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma.
Böhm M; Ittenson A; Klatte T; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
Folia Biol (Praha); 2003; 49(2):63-8. PubMed ID: 12779014
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
6. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
8. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response.
Lauerova L; Dusek L; Simickova M; Kocák I; Vagundová M; Zaloudík J; Kovarík J
Neoplasma; 2002; 49(3):159-66. PubMed ID: 12098001
[TBL] [Abstract][Full Text] [Related]
9. Serum cytokine levels and type 1 and type 2 intracellular T cell cytokine profiles in mixed connective tissue disease.
Bodolay E; Aleksza M; Antal-Szalmás P; Végh J; Szodoray P; Soltész P; Szegedi A; Szekanecz Z
J Rheumatol; 2002 Oct; 29(10):2136-42. PubMed ID: 12375323
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
11. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer.
Macciò A; Lai P; Santona MC; Pagliara L; Melis GB; Mantovani G
Gynecol Oncol; 1998 Jun; 69(3):248-52. PubMed ID: 9648596
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
[TBL] [Abstract][Full Text] [Related]
13. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma.
Komai Y; Saito K; Sakai K; Morimoto S
BJU Int; 2007 Jan; 99(1):77-80. PubMed ID: 16956357
[TBL] [Abstract][Full Text] [Related]
14. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
[TBL] [Abstract][Full Text] [Related]
15. Soluble immunological parameters and early prognosis of renal cell cancer patients.
Kallio JP; Tammela TL; Marttinen AT; Kellokumpu-Lehtinen PL
J Exp Clin Cancer Res; 2001 Dec; 20(4):523-8. PubMed ID: 11876546
[TBL] [Abstract][Full Text] [Related]
16. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy.
Verra N; de Jong D; Bex A; Batchelor D; Dellemijn T; Sein J; Nooijen W; Meinhardt W; Horenblas S; de Gast G; Vyth-Dreese F
Eur Urol; 2005 Sep; 48(3):527-33. PubMed ID: 16115526
[TBL] [Abstract][Full Text] [Related]
17. Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients.
Sartore-Bianchi A; Soriani A; Mattioni R; Vaglio A; Buzio C; Porta C
Oncol Rep; 2004 Oct; 12(4):855-9. PubMed ID: 15375512
[TBL] [Abstract][Full Text] [Related]
18. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
19. Cytokine therapy for metastatic renal cell carcinoma.
Bukowski RM
Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
[TBL] [Abstract][Full Text] [Related]
20. [Serum soluble interleukin-2 receptor levels in patients with renal cell carcinoma: a comparison of values before and after surgery].
Tsukamoto S; Ishikawa S; Yamauchi A; Saitou S
Hinyokika Kiyo; 2000 Oct; 46(10):695-9. PubMed ID: 11215193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
